For research use only
| Cat No. | ABC-TC0882 |
| Product Type | Human Ovarian Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Ovary |
OVKATE: A tumorigenic, EGFR-positive ovarian cancer cell line. Derived from serous adenocarcinoma, it's ideal for targeted therapy & biomarker research.
OVKATE is a human ovarian serous carcinoma cell line derived from a patient with high-grade serous ovarian cancer. These cells grow adherently in culture, exhibiting polygonal, epithelial-like morphology and can be continuously passaged. OVKATE cells express epithelial markers such as cytokeratins and the ovarian cancer biomarker CA125 (MUC16), reflecting their ovarian epithelial origin. They are also positive for vimentin, epithelial membrane antigen (EMA), and epidermal growth factor receptor (EGFR). Genetically, they harbor mutations commonly found in high-grade serous ovarian cancer, including alterations in TP53, which contribute to their aggressive phenotype. OVKATE cells are widely used as an in vitro model to study ovarian cancer biology, tumor progression, and mechanisms of chemoresistance. Their characteristics make them valuable for drug screening and the investigation of targeted therapies in ovarian cancer research.
| Species | Human |
| Cat.No | ABC-TC0882 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Ovary |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Ovarian Cancer Cell Lines |
The OVKATE cell line is a key model for human ovarian carcinoma research. It is used in genomics studies and for establishing xenograft models, allowing in-depth exploration of the molecular mechanisms underlying ovarian cancer. In addition, OVKATE cells support investigations into the regulation of intermediate filament expression and are employed in testing the anti-proliferative effects of candidate drugs, facilitating the development of innovative therapies for ovarian cancer.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
OVKATE cells were originally isolated from ovary of a stage IIIc ovarian tumor patient.
The OVKATE cell line grow slowly. The doubling time would be over 1 week.
Yes. Cells are form tumors by SC injection.
